0001683168-24-001207.txt : 20240227 0001683168-24-001207.hdr.sgml : 20240227 20240227141403 ACCESSION NUMBER: 0001683168-24-001207 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230530 FILED AS OF DATE: 20240227 DATE AS OF CHANGE: 20240227 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Choe Zia CENTRAL INDEX KEY: 0002013089 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-49709 FILM NUMBER: 24685222 MAIL ADDRESS: STREET 1: 3753 HOWARD HUGHES PARKWAY STREET 2: SUITE 200 CITY: LAS VEGAS STATE: NV ZIP: 89169 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cardiff Lexington Corp CENTRAL INDEX KEY: 0000811222 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 841044583 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3753 HOWARD HUGHES PARKWAY STREET 2: SUITE 200 CITY: LAS VEGAS STATE: NV ZIP: 89169 BUSINESS PHONE: 844-628-2100 MAIL ADDRESS: STREET 1: 3753 HOWARD HUGHES PARKWAY STREET 2: SUITE 200 CITY: LAS VEGAS STATE: NV ZIP: 89169 FORMER COMPANY: FORMER CONFORMED NAME: CARDIFF INTERNATIONAL INC DATE OF NAME CHANGE: 20000211 FORMER COMPANY: FORMER CONFORMED NAME: UNITED AMERICAN INC DATE OF NAME CHANGE: 19910924 FORMER COMPANY: FORMER CONFORMED NAME: CARDIFF FINANCIAL INC DATE OF NAME CHANGE: 19890510 4 1 ownership.xml X0508 4 2023-05-30 0 0000811222 Cardiff Lexington Corp CDIX 0002013089 Choe Zia 3753 HOWARD HUGHES PARKWAY, SUITE 200 LAS VEGAS NV 890169 0 1 0 0 Interim CFO 0 Series B Preferred Stock 2023-05-30 4 J 0 3150 0.00 A 2023-05-30 Common Stock 3150 D On May 30, 2023, the Reporting Person received 3,150 shares of Series B Preferred Stock as partial compensation for the Reporting Person's services as Interim Chief Financial Officer of the Issuer. Each share of Series B Preferred Stock is convertible into such number of shares of Common Stock as is determined as follows: (i) if the closing market price of the Common Stock on the principal trading market on which the Common Stock is then traded or quoted is less than $4.00 per share, then each share of Series B Preferred Stock shall be convertible into a number of shares of Common Stock equal to two (2) times the stated value ($4.00 per share), divided by such closing market price on the date of conversion; or (ii) if such closing market price is equal to or greater than $4.00 per share, then each share of Series B Preferred Stock shall be convertible into two (2) shares of Common Stock. The Series B Preferred Stock has no expiration date. /s/ Zia Choe 2024-02-27